Quintiles Transnational.

• Position: Triangle - CV Therapeutics Inc. - Brief Article

DURHAM -- Drug researcher Quintiles Transnational sold the rights to Ranexa, a chronic-angina treatment in the final stages of U.S. Food and Drug Administration approval, back to Palo Alto, Calif.-based CV Therapeutics for 200,000 shares of CV's common stock. The companies had owned the rights jointly under an agreement in...